Paeoniflorin inhibits pyruvate dehydrogenase kinase 3 and promotes BDNF activity by modulating neuronal activity and...

Area of Science:

• Biochemistry and Neurobiology
• Drug Discovery and Development

Background:

• Metabolic dysregulation underlies diseases like diabetes and cancer, implicating pyruvate dehydrogenase kinases (PDKs) as therapeutic targets.
• The specific role of PDK3 in memory loss and Alzheimer's disease (AD) remains underexplored, despite the broader implications of PDKs.
• Neuroinflammation and oxidative stress are key pathological features of AD, contributing to neuronal dysfunction and death.

Purpose of the Study:

• To investigate the potential of PF in mitigating PDK3-associated toxicity relevant to neurodegenerative diseases, particularly AD.
• To elucidate the molecular interactions between PF and PDK3 and assess PF's inhibitory effects on PDK3 activity.
• To evaluate the neuroprotective effects of PF in an in vitro model of SCP-induced toxicity, focusing on cellular viability, oxidative stress, apoptosis, and inflammatory markers.

Main Methods:

• Molecular docking and biophysical characterization were employed to understand PF-PDK3 interactions.
• In vitro assays were used to determine PF's inhibitory concentration (IC50) against PDK3.
• SCP-induced toxicity model in neuronal cells was utilized to assess PF's effects on cell viability, reactive oxygen species (ROS) production, apoptosis, TNF-α expression, and BDNF expression following pre-treatment with varying PF concentrations.

Main Results:

• PF demonstrated significant inhibition of PDK3 activity in a concentration-dependent manner, with an IC50 of 4.88 µM.
• PF pre-treatment enhanced cell viability, suppressed ROS generation, reduced apoptosis, and downregulated TNF-α expression in SCP-treated neuronal cells.
• PF treatment increased the expression of BDNF, a marker of memory function, with optimal effects observed at lower and moderate doses.

Conclusions:

• PF effectively inhibits PDK3 activity and exhibits significant neuroprotective effects against SCP-induced toxicity in vitro.
• PF's multifaceted actions, including enhancing cell viability, reducing oxidative stress and apoptosis, and downregulating inflammation, suggest its therapeutic potential for AD.
• PF demonstrates potential as a dose-dependent therapeutic agent for Alzheimer's disease by improving memory markers and mitigating neurodegenerative processes.